Active substances
Lidocaine + Methylprednisolone
- Health Canada 1
- UK MHRA 1
- NHS prices 2
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| DEPO-MEDROL WITH LIDOCAINE | 00260428 | 40 MG / ML; 10 MG / ML | SUSPENSION · INTRA-ARTICULAR; PERIARTICULAR; INTRASYNOVIAL; INTRABURSAL | PFIZER CANADA ULC |
UK MHRA United Kingdom — marketing authorisations
| Product | Authorisation | Holder | Legal status |
|---|---|---|---|
| DEPO-MEDRONE WITH LIDOCAINE 40/10 MG/1 ML SUSPENSION FOR INJECTION | PL 00057/0964 | PFIZER LIMITED | POM |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| NHS Drug Tariff | Methylprednisolone 40mg/1ml / Lidocaine 10mg/1ml (1%) suspension for injection vials | £3.94 | 1 vial | 1 Oct 2026 |
| NHS Drug Tariff | Methylprednisolone 80mg/2ml / Lidocaine 20mg/2ml (1%) suspension for injection vials | £7.06 | 1 vial | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Components
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), MHRA category lists of UK marketing authorisations (Open Government Licence v3.0), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.